share_log

T2 Biosystems | S-3: Registration statement for specified transactions by certain issuers

T2 Biosystems | S-3: Registration statement for specified transactions by certain issuers

T2 Biosystems | S-3：特定交易註冊聲明
美股sec公告 ·  05/28 18:06
牛牛AI助理已提取核心訊息
T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, has filed a Form S-3 registration statement with the Securities and Exchange Commission (SEC) on May 24, 2024. The registration pertains to the resale of up to 6,217,723 shares of common stock by selling stockholders. These shares include 1,700,000 currently outstanding shares, shares issuable upon the exercise of various warrants acquired in a private placement transaction on May 17, 2024, and shares issuable upon the exercise of Wainwright Warrants. T2 Biosystems will not sell any shares or receive proceeds from the selling stockholders' sales, but will receive proceeds if the warrants are exercised for cash. The selling stockholders will cover all commissions and discounts from their sales, while T2 Biosystems will bear all other costs associated with the registration. The common stock is traded on The NASDAQ Capital Market under the symbol 'TTOO', with the last reported sale price being $5.16 per share as of May 23, 2024. The company cautions that investing in its common stock involves a high degree of risk.
T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, has filed a Form S-3 registration statement with the Securities and Exchange Commission (SEC) on May 24, 2024. The registration pertains to the resale of up to 6,217,723 shares of common stock by selling stockholders. These shares include 1,700,000 currently outstanding shares, shares issuable upon the exercise of various warrants acquired in a private placement transaction on May 17, 2024, and shares issuable upon the exercise of Wainwright Warrants. T2 Biosystems will not sell any shares or receive proceeds from the selling stockholders' sales, but will receive proceeds if the warrants are exercised for cash. The selling stockholders will cover all commissions and discounts from their sales, while T2 Biosystems will bear all other costs associated with the registration. The common stock is traded on The NASDAQ Capital Market under the symbol 'TTOO', with the last reported sale price being $5.16 per share as of May 23, 2024. The company cautions that investing in its common stock involves a high degree of risk.
T2 Biosystems, Inc. 是快速檢測誘發敗血症的病原體和抗生素耐藥基因領域的領導者，已於2024年5月24日向美國證券交易委員會（SEC）提交了S-3表格註冊聲明。該註冊涉及通過出售股東轉售多達6,217,723股普通股。這些股票包括目前已發行的1,700,000股股票、在行使2024年5月17日私募交易中收購的各種認股權證後可發行的股票以及在行使溫賴特認股權證時可發行的股份。T2 Biosystems不會出售任何股票或從出售股東的銷售中獲得收益，但如果認股權證以現金行使，則將獲得收益。出售股東將支付其銷售中的所有佣金和折扣，而T2 Biosystems將承擔與註冊相關的所有其他費用。普通股在納斯達克資本市場上交易，股票代碼爲 “TTOO”，截至2024年5月23日，最新公佈的銷售價格爲每股5.16美元。該公司警告說，投資普通股涉及高度的風險。
T2 Biosystems, Inc. 是快速檢測誘發敗血症的病原體和抗生素耐藥基因領域的領導者，已於2024年5月24日向美國證券交易委員會（SEC）提交了S-3表格註冊聲明。該註冊涉及通過出售股東轉售多達6,217,723股普通股。這些股票包括目前已發行的1,700,000股股票、在行使2024年5月17日私募交易中收購的各種認股權證後可發行的股票以及在行使溫賴特認股權證時可發行的股份。T2 Biosystems不會出售任何股票或從出售股東的銷售中獲得收益，但如果認股權證以現金行使，則將獲得收益。出售股東將支付其銷售中的所有佣金和折扣，而T2 Biosystems將承擔與註冊相關的所有其他費用。普通股在納斯達克資本市場上交易，股票代碼爲 “TTOO”，截至2024年5月23日，最新公佈的銷售價格爲每股5.16美元。該公司警告說，投資普通股涉及高度的風險。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。